DK1294390T3 - Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet - Google Patents
Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitetInfo
- Publication number
- DK1294390T3 DK1294390T3 DK01906632T DK01906632T DK1294390T3 DK 1294390 T3 DK1294390 T3 DK 1294390T3 DK 01906632 T DK01906632 T DK 01906632T DK 01906632 T DK01906632 T DK 01906632T DK 1294390 T3 DK1294390 T3 DK 1294390T3
- Authority
- DK
- Denmark
- Prior art keywords
- cop
- nervous system
- polypeptide
- polypeptides
- copolymer
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
- 229920001577 copolymer Polymers 0.000 title 1
- 229930195712 glutamate Natural products 0.000 title 1
- 230000004112 neuroprotection Effects 0.000 title 1
- 230000001988 toxicity Effects 0.000 title 1
- 231100000419 toxicity Toxicity 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 210000005036 nerve Anatomy 0.000 abstract 2
- 210000000653 nervous system Anatomy 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 2
- 230000008929 regeneration Effects 0.000 abstract 2
- 238000011069 regeneration method Methods 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46432—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Marine Sciences & Fisheries (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20979900P | 2000-06-07 | 2000-06-07 | |
| US62021600A | 2000-07-20 | 2000-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1294390T3 true DK1294390T3 (da) | 2006-04-03 |
Family
ID=26904524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01906632T DK1294390T3 (da) | 2000-06-07 | 2001-01-22 | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20020037848A1 (es) |
| EP (1) | EP1294390B1 (es) |
| JP (1) | JP4328090B2 (es) |
| KR (1) | KR20030007397A (es) |
| CN (1) | CN100438906C (es) |
| AT (1) | ATE314860T1 (es) |
| AU (1) | AU783031B2 (es) |
| CA (1) | CA2398277C (es) |
| CY (1) | CY1105263T1 (es) |
| DE (1) | DE60116467T2 (es) |
| DK (1) | DK1294390T3 (es) |
| ES (1) | ES2256200T3 (es) |
| HK (1) | HK1058892A1 (es) |
| IL (2) | IL150801A0 (es) |
| MX (1) | MXPA02007109A (es) |
| NZ (1) | NZ520282A (es) |
| WO (1) | WO2001093893A2 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| PL363431A1 (en) * | 2000-06-05 | 2004-11-15 | Teva Pharmaceuticals Industries, Ltd. | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| WO2003047500A2 (en) * | 2001-12-06 | 2003-06-12 | Yeda Research And Development Co. Ltd | Vaccine and method for treatment of motor neurone diseases |
| AU2002353059B2 (en) | 2001-12-04 | 2008-06-19 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
| EP1583506B1 (en) * | 2003-01-07 | 2012-03-07 | Yeda Research And Development Co., Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| CA2540701A1 (en) * | 2003-09-29 | 2005-04-07 | Chugai Seiyaku Kabushiki Kaisha | Proteins expressed in nk cells |
| US7585843B2 (en) * | 2003-10-03 | 2009-09-08 | Bayhill Therapeutics, Inc. | Treatment of demyelinating autoimmune disease with modified ordered peptides |
| EP1684797A1 (en) * | 2003-11-12 | 2006-08-02 | Yeda Research and Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| SI1701730T1 (sl) * | 2003-12-09 | 2014-01-31 | Yeda Research And Development Co. Ltd. The Weizmann Institute Of Science | Postopek in cepivo, ki obsega kopolimer 1 za zdravljenje psihiatriäśnih motenj |
| EP1750742A2 (en) | 2004-05-07 | 2007-02-14 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| ES2451006T3 (es) | 2004-09-09 | 2014-03-26 | Teva Pharmaceutical Industries Ltd. | Procedimiento para la preparación de mezclas de acetato de trifluoroacetilglatirámero usando ácido bromhídrico purificado |
| EP1827108B1 (en) * | 2004-11-29 | 2015-04-08 | Yeda Research And Development Co., Ltd. | Induction of neurogenesis and stem cell therapy in combination with copolymer 1 |
| JP2009536157A (ja) | 2006-04-13 | 2009-10-08 | ペプチミューン，インコーポレイテッド | エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法 |
| WO2009040814A1 (en) | 2007-09-24 | 2009-04-02 | Hadasit Medical Research Services & Development Ltd | Use of copolymer 1 for treatment of muscular dystrophy |
| AP3467A (en) | 2007-10-16 | 2015-11-30 | Peptimmune Inc | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
| WO2009063459A2 (en) * | 2007-11-13 | 2009-05-22 | Yeda Research And Development Co. Ltd | Synthetic peptide copolymers for treatment of neurodevelopmental disorders |
| KR20170123354A (ko) | 2009-08-20 | 2017-11-07 | 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 | 글라티라머 아세테이트를 포함하는 약제 |
| WO2011080733A1 (en) | 2010-01-04 | 2011-07-07 | Mapi Pharma Limited | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| WO2012051106A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
| AU2012323345A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| EP2892353A4 (en) | 2012-09-10 | 2016-10-26 | Yeda Res & Dev | INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA |
| EP3600553A4 (en) | 2017-03-26 | 2020-09-02 | Mapi Pharma Ltd. | GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS |
| KR20230128606A (ko) * | 2022-02-28 | 2023-09-05 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| IL137761A0 (en) * | 1998-02-13 | 2001-10-31 | Autoimmune Inc | Treatment of multiple sclerosis using cop-1 and th-2 enhancing cytokines |
-
2001
- 2001-01-22 MX MXPA02007109A patent/MXPA02007109A/es active IP Right Grant
- 2001-01-22 WO PCT/US2001/002118 patent/WO2001093893A2/en active IP Right Grant
- 2001-01-22 ES ES01906632T patent/ES2256200T3/es not_active Expired - Lifetime
- 2001-01-22 CA CA2398277A patent/CA2398277C/en not_active Expired - Lifetime
- 2001-01-22 DK DK01906632T patent/DK1294390T3/da active
- 2001-01-22 CN CNB018065910A patent/CN100438906C/zh not_active Expired - Lifetime
- 2001-01-22 NZ NZ520282A patent/NZ520282A/en not_active IP Right Cessation
- 2001-01-22 AT AT01906632T patent/ATE314860T1/de active
- 2001-01-22 IL IL15080101A patent/IL150801A0/xx active IP Right Grant
- 2001-01-22 JP JP2002501464A patent/JP4328090B2/ja not_active Expired - Fee Related
- 2001-01-22 US US09/765,301 patent/US20020037848A1/en not_active Abandoned
- 2001-01-22 AU AU34518/01A patent/AU783031B2/en not_active Expired
- 2001-01-22 EP EP01906632A patent/EP1294390B1/en not_active Expired - Lifetime
- 2001-01-22 DE DE60116467T patent/DE60116467T2/de not_active Expired - Lifetime
- 2001-01-22 KR KR1020027009275A patent/KR20030007397A/ko not_active Application Discontinuation
-
2002
- 2002-07-18 IL IL150801A patent/IL150801A/en unknown
-
2004
- 2004-03-05 HK HK04101665.8A patent/HK1058892A1/xx not_active IP Right Cessation
-
2006
- 2006-02-16 CY CY20061100219T patent/CY1105263T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001093893A2 (en) | 2001-12-13 |
| MXPA02007109A (es) | 2002-12-13 |
| JP4328090B2 (ja) | 2009-09-09 |
| NZ520282A (en) | 2004-09-24 |
| WO2001093893A3 (en) | 2002-04-04 |
| IL150801A (en) | 2007-10-31 |
| DE60116467D1 (de) | 2006-03-30 |
| JP2004507460A (ja) | 2004-03-11 |
| ATE314860T1 (de) | 2006-02-15 |
| AU783031B2 (en) | 2005-09-15 |
| US20020037848A1 (en) | 2002-03-28 |
| HK1058892A1 (en) | 2004-06-11 |
| EP1294390B1 (en) | 2006-01-04 |
| CA2398277C (en) | 2013-09-03 |
| DE60116467T2 (de) | 2006-11-02 |
| ES2256200T3 (es) | 2006-07-16 |
| CA2398277A1 (en) | 2001-12-13 |
| EP1294390A2 (en) | 2003-03-26 |
| CY1105263T1 (el) | 2010-03-03 |
| CN1462190A (zh) | 2003-12-17 |
| CN100438906C (zh) | 2008-12-03 |
| KR20030007397A (ko) | 2003-01-23 |
| AU3451801A (en) | 2001-12-17 |
| IL150801A0 (en) | 2003-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1294390T3 (da) | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet | |
| DK1248643T3 (da) | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi | |
| TR199802421T2 (xx) | Doku yenilenmesini d�zenleyen maddeler. | |
| NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
| ATE186219T1 (de) | Kombination von antihormonale und bindende moleküle zur krebsbehandlung | |
| ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| WO1999060021A3 (en) | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system | |
| HUP9904023A2 (hu) | Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban | |
| ATE255128T1 (de) | Peptid-immitierende substanzen in der krebstherapie | |
| DE69835279D1 (de) | Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika | |
| DK0914144T3 (da) | Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi | |
| DE60032486D1 (de) | Prion protein peptide und deren verwendung | |
| AR045870A1 (es) | Terapia de combinacion para la infeccion de virus de hepatitis c | |
| ATE234111T1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
| WO2003103573A3 (en) | METHODS OF TREATING A NEUROLOGICAL DISORDER BY PERIPHERAL DELIVERY OF A TROPHIC FACTOR | |
| WO1996020950A3 (en) | Compositions and methods for treating rheumatoid arthritis | |
| DE68906066D1 (de) | Peptid und dessen salze und antiallergische peptidmittel, welche diese peptide enthalten. | |
| DE60332481D1 (de) | Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems | |
| DE60121449D1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon | |
| EA200000514A1 (ru) | Способ лечения эректильной дисфункции |